60 Participants Needed

Mobile Health-based Motivational Interviewing for Vaccine Hesitancy

(COVID-19 Trial)

Recruiting at 1 trial location
AB
TB
Overseen ByThanh Bui
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Oklahoma State University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The objective of this study is to evaluate the preliminary efficacy and acceptability of an mobile Health-based motivational interviewing (MI) intervention to promote SARS-CoV-2 vaccination (MOTIVACC) compared to traditional phone-based MI.

Eligibility Criteria

This trial is for adults over 18 living in rural areas who haven't had a COVID-19 vaccine and can speak English. They must be able to consent and use a smartphone. It's not for those with certain medical/psychiatric conditions, involved in other COVID studies, or pregnant/lactating women.

Inclusion Criteria

18 years or older
Reside in a rural area
No previous dose of a SARS-CoV-2 vaccine
See 2 more

Exclusion Criteria

Inability to participate because of medical or psychiatric conditions diagnosed by a physician/clinician
Pregnant or lactating
You have a condition that makes it difficult for you to use a smartphone or affects your thinking ability.
See 1 more

Treatment Details

Interventions

  • MOTIVACC
Trial OverviewThe study tests if mobile Health-based motivational interviewing (MOTIVACC) encourages people to get vaccinated against COVID-19 more effectively than traditional phone calls. Participants will receive different types of motivational messages.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Standard MIExperimental Treatment2 Interventions
Group II: MOTIVACCExperimental Treatment2 Interventions
Group III: Intensive MIExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Oklahoma State University

Lead Sponsor

Trials
51
Recruited
8,600+

University of Oklahoma

Collaborator

Trials
484
Recruited
95,900+